The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with ...
GlobalData on MSN8d
FDA approves Gomekli as first neurofibromatosis drug for adultsThe US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...
Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...
Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by ...
The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat neurofibromatosis type 1 (NF1), a type of rare genetic disorder. Both adult and ...
Gomekli is the second ever FDA-approved treatment for rare tumor disease, NF1-PN and the first to be approved for both adult ...
SpringWorks Therapeutics has announced the FDA approval of GOMEKLI (mirdametinib), the first medication for both adults and children aged 2 and older with neurofibromatosis type 1 (NF1 ...
Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...
GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data ...
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback